A Randomized Double-Blind Placebo-Controlled Single Ascending Dose Study to Assess the Safety Tolerability and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this Phase I study is to see whether a single dose of an experimental drug (meaning a drug that is not approved by the FDA) called C2 N-8E 12 given into your vein (called intravenous or IV) is safe and well-tolerated in subjects with Progressive Supranuclear Palsy (PSP).
Description
The purpose of this study is to see whether a single dose of a drug called C2N-8E12 given to subjects via IV infusion is safe and well-tolerated in subjects with Progressive Supranuclear Palsy.
Details
| Condition | progressive supranuclear palsy |
|---|---|
| Age | 50years - 85years |
| Clinical Study Identifier | TX5967 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.